目的 对晚期非小细胞肺癌(NSCLC)患者进行回顾性分析,探讨参一胶囊维持治疗对患者炎症因子的影响。方法 经参一胶囊联合化疗一线治疗后取得缓解或稳定的37名晚期NSCLC患者意向性分为治疗组(A组,21人)和对照组(B组,16人)。A组继续服用参一胶囊每天2次,每次20 mg,服药至疾病进展或无法耐受;B组未予特殊治疗。分别于第1 d、90 d采血,检测白细胞计数、中性粒细胞计数、C反应蛋白、肿瘤坏死因子α(TNF-α)、白细胞介素1β(IL-1β)、白细胞介素1α(IL-1α)、白细胞介素6(IL-6)和白细胞介素10(IL-10)。结果 治疗前后比较,治疗组各项炎症指标均未发生明显变化(P>0.05);而对照组的TNF-α、IL-1β、IL-6上升(P值分别为<0.001、0.032、0.001),IL-10下降(P=0.035);治疗后两组间比较,对照组TNF-α、IL-1β、IL-6上升(P值分别为<0.001、0.001、0.004),IL-10则下降(P=0.002)。两组间IL-1α及白细胞计数、中性粒细胞计数、C反应蛋白无变化(P>0.05)。结论 参一胶囊维持治疗可使晚期NSCLC患者TNF-α、IL-1β及IL-6的低表达,提示调节炎症反应可能是参一胶囊维持治疗抑制NSCLC进展的机制之一。

Objective To retrospectively investigate the influence of Shenyi Capsule maintenance therapy on inflammatory factors in patients with advanced NSCLC. Methods Thirty seven patients with advanced NSCLC, who had become palliative or stable after first-line treatment with combined Shenyi capsule chemotherapy, were intentionally assigned to treatment group (group A, 21 patients) and control group (group B, 16 patients). Shenyi capsule was given to group A (20mg p.o., bid) until appearance of deterioration or intolerance, while no special treatment was given to group B. Leukocytes, neutrophils, C-reactive protein, tumor necrosis factor α (TNF-α), interleukin-1β(IL-1β), interleukin-1α (IL-1α),interleukin-6(IL-6) and interleukin-10(IL-10) were tested by blood specimens taken respectively on 1st day and 90th day. Results There were no statistical differences (P>0.05) between the level of inflammatory factors on 1th day and 90th day in treatment group. In control group, however, TNF-α、IL-1β and IL-6 increased (P<0.001, P=0.032、P=0.001 respectively) and IL-10 decreased significantly (P=0.035). Furthermore, the level of TNF-α、IL-1β and IL-6 in treatment group were also higher (P<0.001, P=0.001, P=0.004 respectively), while IL-10 was lower (P=0.002)than control group on 90th day. There were no statistical differences(P>0.05)between the two groups in the level of IL-1α, leukocyte, neutrophils or C reactive protein on 1th day and 90th day. Conclusion Shenyicapsule maintenance therapy could lower the expression of TNF-α、IL-1β and IL-6 in patients with advanced NSCLC, which indicates that the regulation of inflammatory reaction may be one of the mechanisms of inhibition from NSCLC progression in Shenyi capsule maintenance therapy.

目的 对比紫杉醇脂质体(LEP)与紫杉醇(PTX)联合顺铂(DDP)治疗晚期非小细胞肺癌(NSCLC)的临床疗效及安全性。方法 晚期NSCLC患者48例,随机分为对照组和试验组,对照组采用紫杉醇175 mg/m²,试验组采用紫杉醇脂质体175 mg/m²,均联合顺铂75 mg/m²化疗,21天为1个周期,治疗2个周期后评价疗效,记录近期疗效与治疗期间不良反应。结果 近期疗效:对照组有效率37.50%,疾病控制率为79.17%,试验组有效率为41.67%,疾病控制率为83.33%,两组差异均无统计学意义(P>0.05)。不良反应:白细胞减少、贫血及血小板减少的发生率两组差异无统计学意义(P>0.05),脱发和恶心、呕吐的发生率两组差异亦无统计学意义(P>0.05),但试验组皮疹、呼吸困难、肌肉痛及周围神经炎的发生率明显低于对照组,差异有统计学意义(P<0.05)。结论 紫杉醇脂质体治疗晚期NSCLC与紫杉醇疗效相当,但周围神经炎及过敏反应较紫杉醇为轻。

Objective To compare the efficacy and safety of paclitaxel liposome combined with cisplatin and paclitaxel combined with cisplatin in the treatment of advanced non-small cell lung cancer (NSCLC). Methods 48 patients with advanced NSCLC were randomized into two groups, experimental group were given paclitaxel liposome at 175 mg/m²,and control group were given paclitaxel at 175 mg/m². Both groups combined with DDP at 75 mg/m² per cycle every 21 days.The efficacy and safety were evaluated after two cycles. Results The overall response rate was 37.50% in experimental group and 41.67% in control group, and the disease control rate was 79.17% in experimental group and 83.33% in control group. There was no significant difference between two groups(P>0.05). Though there was no significant difference in incidence of neutropenia,anemia, thrombocytopenia and alopecia, nausea and vomiting, but the occurred rates of rash、muscle pain and peripheral neuritis were significantly lower in experimental group than those in control group. Conclusion In the treatment of advanced NSCLC, both paclitaxel liposome combined with cisplatin and paclitaxel combined with cisplatin have similar efficacy, but paclitaxel liposome can significantly reduce the incidence of peripheral neuritis and serious hypersensitive reactions.

目的 探讨同步放化疗治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法 选取我院2014年收治的晚期NSCLC患者102例,随机分为观察组和对照组,对照组以紫杉醇联合顺铂化疗方案(TP)化疗治疗,观察组加用三维适形放疗同步放化疗治疗,观察两组的临床疗效和不良反应。结果 观察组和对照组患者的总有效率分别为43.14%和21.57% (P<0.05),两组患者的总控制率分别为84.31%和66.67% (P<0.05)。两组患者Ⅲ～Ⅳ级胃肠道反应、白细胞减少、骨髓抑制的发生率差异无统计学意义(P>0.05),观察组比对照组增加了放射性肺炎和放射性食管炎的发生 (P<0.05)。两组患者生活质量比较,差异具有统计学意义(P＜0.05)。结论 同步放化疗治疗晚期NSCLC可以显著提高治疗的总有效率、肿瘤的控制率及生活质量,但也使不良反应增加,选择治疗方案时应根据个体情况综合考虑。

Objective To study the clinical efficacy of concurrent chemoradiotherapy in the treatment of advanced non small cell lung cancer (NSCLC). Methods 102 cases of advanced NSCLC treated in our hospital in 2014 were selected and randomly divided into the observation group and the control group. Patients in control group were treated by chemotherapy with Paclitaxel combined Cisplatin (TP), while those in observation group were treated by concurrent chemoradiotherapy with three- dimensional conformal radiotherapy and TP. The clinical efficacy and adverse reactions of the two groups were observed. Results The total effective rate of the observation group and the control group were 43.14% and 21.57% (P<0.05), respectively. The total control rate of the two groups were 84.31% and 66.67%(P<0.05). In two groups III ~ IV gastrointestinal tract reaction, leukopenia, bone marrow suppression occurrence had no statistical significance(P>0.05). Incidence of radiation pneumonitis and radiation esophagitis increased in observation group(P<0.05). The difference of quality of life between the two groups was statistically significant(P<0.05). Conclusion Concurrent radiotherapy and chemotherapy in the treatment ofadvanced non-small cell lung cancer(NSCLC)can not only significantly improve the treatment, tumor control rate and quality of life, but also make adverse reaction increased. Treatment options should be chosen based on individual circumstances into account

目的 探讨生血宁片对缺铁性贫血孕妇的治疗效果。方法 选取90个缺铁性贫血孕妇为研究对象,随机分为A、B、C三组,每组30人,从孕28周开始治疗,A组服用多糖铁复合物,B组口服生血宁片,C组采用营养科建议的补铁食疗菜谱,一直治疗至分娩前,治疗前后各检测血常规,血红蛋白(Hb)、红细胞比容(HCT)、红细胞平均体积(MCV)、红细胞平均血红蛋白浓度(MCHC)对比治疗效果。结果 服药前各组孕妇的血Hb、RBC、HCT、MCV、MCH无统计学差异,A、B组服药后Hb、RBC、HCT、MCV、MCH均高于服药前,且结果有统计学意义(P＜0.05),C组食疗前、后Hb、RBC、HCT、MCV、MCH无统计学差异,A、B、C三组之间Hb、RBC、HCT、MCV、MCH对比结果为,A、B组之间Hb、RBC、HCT、MCV、MCH差异无统计学意义(P＞0.05),但均高于C组,差异有统计学意义(P＜0.05)。结论 生血宁对孕晚期缺铁性贫血的孕妇有治疗作用,且效果与多糖铁复合物相当。

Objective To investigate the therapeutic effect of Shengxuening tablets on iron deficiency anemia in pregnant women. Methods Selected A total of 90 pregnant women with iron deficiency anemia as the research objects, randomly divided into A, B, C three groups. Each group of 30 people was treated since 28 weeks of pregnancy. Group A was treated with polysaccharide iron complex, group B with Shengxuening tablets, group C with the nutritionist recommended iron diet recipes. They have been treated till delivery. Before and after treatment, blood routine examination, the value of Hb,RBC,HCT,MCV,MCH had contrast treatment. Results There was no significant difference of serum Hb,RBC,HCT,MCV,MCH in the pregnant women before treatment. After treatment, Hb,RBC,HCT,MCV,MCH of group A, B were higher than before, and the results were statistically significant(P＜0.05). Before therapy of group C, there was no significant difference, in the three groups, results of Hb,RBC,HCT,MCV,MCH, there was no statistical difference between group A, B (P＞0.05), but both were higher than group C, the difference was statistically significant(P＜0.05). Conclusion There was therapeutic effect of Shengxuening in late pregnant women with iron deficiency anemia, and it is equal to the effect of Polysaccharide iron complex treatment.

       目的   分析贝伐珠单抗与化疗对晚期结直肠癌患者4种错配修复蛋白（MSH2、MLHI、MSH6、PMS2）水平影响。方法   选择2022年1月—2024年1月江苏省宿迁市中医院肿瘤科102例晚期结直肠癌患者，按抽签法分成两组，即化疗组及联合组，各51例。化疗组应用FOLFOX（亚叶酸钙+奥沙利铂+氟尿嘧啶）方案进行化疗，联合组采取贝伐珠单抗联合FOLFOX方案治疗。对比其肿瘤控制效果、免疫功能及MSH2、MLHI、MSH6和PMS2水平变化，并对比组间不良反应发生率。结果   联合组客观缓解率、疾病控制率高于化疗组（P＜0.05）；治疗后联合组患者CD4⁺ 、CD3⁺ 、CD8⁺ 、和CD4⁺ /CD8⁺数值高于化疗组，且两组治疗后均低于治疗前（P＜0.05）；治疗后两组患者MSH2、MLHI、MSH6和PMS2缺失率对比无统计学意义（P＞0.05），但其阳性、阴性表达情况对比差异有统计学意义，联合组MSH2、MLHI、MSH6和PMS2阳性率低于化疗组（P＜0.05）；两组不良反应发生率对比差异无统计学意义（P＞0.05）。结论   对晚期结直肠癌在化疗基础上增加贝伐珠单抗抗肿瘤效果显著，改善其免疫功能，虽无法改善患者错配修复蛋白缺损，但可辅助降低其阳性率，且不影响安全性。

       Objective  To analyze the effects of bevacizumab and chemotherapy on the levels of four mismatch  repair proteins（MSH2，MLHI，MSH6，PMS2）in patients with advanced colorectal cancer．Methods  A total of 102 patients with advanced colorectal cancer from the Oncology Department of Suqian Traditional Chinese Medicine Hospital in  Jiangsu Province from January 2022 to January 2024 were selected，and were divided into two groups according to the drawing method，namely the chemotherapy group and the combination group，with 51 patients in each group．The chemotherapy group received FOLFOX（calcium folinate+oxaliplatin+fluorouracil）regimen for chemotherapy，while the combination group received bevacizumab combined with FOLFOX regimen for treatment．Tumor control effect，immune function，and changes in MSH2，MLHI，MSH6，and PMS2 levels，and its incidence of adverse reactions were compared．Results  The objective remission rate and disease control rate of the combined group were higher than those of the chemotherapy group（P＜0.05）．After treatment，the CD4⁺ ，CD3⁺ ，CD8⁺ and CD4⁺ /CD8⁺ values in the combination group were higher than those in the chemotherapy group，and those after treatment were lower than those before treatment in both groups（P＜0.05）．After treatment，there were no significant differences in the deletion  rates of MSH2，MLHI，MSH6，and PMS2 between the two groups of patients（P＞0.05），but there was a significant difference in their positive and negative expression．The positive rates of MSH2，MLHI，MSH6，and PMS2 in the combination group were lower than those in the chemotherapy group（P＜0.05）．There was no significant difference in the incidence of adverse  reactions between the two groups（P＞0.05）．Conclusions  Adding bevacizumab on the basis of chemotherapy has a significant anti-tumor effect on advanced colorectal cancer，improving its immune function．Although it cannot improve the mismatch  repair protein defect in patients，it can assist in reducing its positivity rate and has high safety．

       目的  探讨晚期早产儿中小于胎龄儿（SGA）与适于胎龄儿（AGA）出生时的铁代谢状态。方法  选取2020年1—12月合肥市妇幼保健院收治的150例晚期早产儿（胎龄34～36⁺⁶周）作为研究对象。按照出生体质量和胎龄将早产儿分为SGA组（36例）和AGA组（114例），分析比较两组早产儿出生时的铁代谢状态，并应用多因素线性回归分析血清铁的影响因素。结果  与AGA组相比，SGA婴儿的更低的血清铁［14.5 μmol /L （11.4，17.1） vs 16.4 μmol /L（14.1，18.4），P=0.004］、更低的血清铁蛋白［135.6 μg/L（101.8，176.2） vs 172.5 μg/L（123.0，218.3），P=0.009］和更低的总铁结合力［30.4 μmol/L（26.8，34.9）vs 35.4 μmol/L（29.5，44.6），P=0.001］。两组早产儿的血红蛋白、平均红细胞体积、平均红细胞血红蛋白含量和平均红细胞血红蛋白浓度比较差异均无统计学意义（P＞0.05）。在早产儿围生期特征中，胎盘异常（β= –1.949，P=0.009）和母亲糖尿病的发生（β= –2.324，P=0.001）与血清铁水平呈负相关。结论  与早产AGA相比，早产SGA铁储备水平较低，适量补充铁元素对小于胎龄新生儿身体发育有促进作用。

      Objective   To explore the iron metabolism status in late preterm infants who are small for gestational age（SGA）compared to those appropriate for gestational age（AGA）at birth．Methods   A total of 150 late preterm infants（gestational age 34 to 36⁺⁶ weeks）admitted to the Maternal and Child Health Hospital of Hefei from January to December 2020 were selected as the study subjects．The preterm infants were divided into the SGA group（36 cases）and the AGA group（114 cases）according to birth weight and gestational age．The iron metabolism status at birth was analyzed and compared between the two groups of preterm infants，and multiple linear regression analysis was applied to identify the influencing factors of serum iron．Results   Compared with the AGA group，SGA infants had lower serum iron（14.5［11.4，17.1］ vs 16.4 ［14.1，18.4］，P=0.004），lower serum iron protein（135.6［101.8，176.2］ vs 172.5［123.0，218.3］，P=0.009），and lower total iron binding capacity（30.4［26.8，34.9］ vs35.4［29.5，44.6］P=0.001）．There were no statistically significant differences in hemoglobin，mean corpuscular volume，mean corpuscular hemoglobin，and mean corpuscular hemoglobin concentration between the two groups of preterm infants（P＞0.05）．Among the perinatal characteristics of preterm infants，placental abnormalities（β= –1.949，P=0.009）and the occurrence of maternal diabetes（β= –2.324，P=0.001）were significantly negatively correlated with serum iron levels．Conclusions  Compared with preterm infants appropriate for gestational age，preterm infants who are small for gestational age have lower iron reserves at birth．Adequate supplementation of iron has a promoting effect on the physical development of small for gestational age newborns．

       目的   探讨免疫治疗联合化学治疗（化疗）对晚期非小细胞肺癌（NSCLC）患者淋巴免疫及生活质量的影响，为临床进一步治疗提供参考。方法  选择2021年6月—2023年6月天津市滨海新区大港医院收治的晚期NSCLC患者120例进行研究，按抽签法分为干预组及对照组，每组60例，对照组采取单纯化疗方案，干预组采取免疫联合化疗方案，对比两组临床疗效、药物不良反应，治疗前后免疫功能（CD3⁺ 、CD4⁺ 、CD8⁺ ）、糖类抗原199（CA199）、糖类抗原 125（CA125）、血清癌胚抗原（CEA）水平及健康状态调查表（QOL）评分。结果  干预组患者治疗总有效率高于对照组（68.33%＞41.67%，P＜0.05）；治疗后干预组患者CD3⁺ 、CD4⁺ 比例高于治疗前及对照组治疗后，CD8⁺ 比例低于治疗前及对照组治疗后（P＜0.05）；治疗后干预组血清CA199、CA125、CEA水平均低于治疗前及对照组治疗后（P＜0.05）；干预组药物不良反应发生率为16.67％，对照组为36.67％，干预组低于对照组（P＜0.05）；治疗后干预组QOL各维度评分高于对照组及治疗前（P＜0.05）。结论  与单纯化疗相比，免疫联合化疗治疗晚期NSCLC患者，能有效降低肿瘤标志物水平，改善患者免疫指标，减轻药物不良反应，提高患者疗效及生活质量。

       Objective  To explore the effect of immunotherapy combined with chemotherapy on lymphatic immunity and quality of life of patients with advanced non-small cell lung cancer（NSCLC），and to provide reference for further clinical treatment．Methods  A total of 120 patients with NSCLC from June 2021 to June 2023 were selected and divided into observation group and control group evenly according to the method of drawing lots，control group was treated with chemotherapy，the observation group was treated with immunotherapy combined with chemotherapy，and the clinical efficacy and adverse drug reactions were compared between the two groups．Before and after treatment，immune function（CD3⁺ ，CD4⁺ ，CD8⁺ ），carbohydrate antigen 199（CA199），carbohydrate antigen 125（CA125），serum carcinoembryonic antigen（CEA）levels and health status questionnaire（QOL-RRB- scores）were measured．Results The total effective  rate in the observation group was significantly higher than that in the control group（68.33%＞41.67%，P＜0.05）．After treatment，the ratios of CD3⁺  and CD4⁺  in the observation group were significantly higher than those before treatment and control group after treatment，and the ratio of CD8⁺  was significantly lower than that before and after treatment in the control group（P＜0.05）．After treatment，the serum levels of CA199，CA125 and CEA in the observation group were lower than those before and after treatment in the control group（P＜0.05）．The incidence of adverse drug  reactions was 16.67% in the observation group and 36.67% in the control group，which was significantly lower in the observation group than in the control group（P＜0.05）．After treatment，the QOL scores in the observation group were significantly higher than those in the control group and before treatment（P＜0.05）．Conclusions  Compared with chemotherapy alone，immunotherapy combined with chemotherapy can effectively reduce the levels of tumor markers，improve the immune indexes of patients，reduce the adverse drug reactions，and improve the efficacy and quality of life of patients with advanced NSCLC．

       目的   探讨免疫及靶向药物联合肝动脉灌注化学治疗（化疗）治疗晚期肝癌的临床疗效。方法   选取甘肃省武威市人民医院2021年1月—2024年1月收治的78例晚期肝癌患者进行回顾性分析，其中20例患者采取单纯肝动脉灌注化疗（HAIC）治疗为单化疗组，30例患者采取HAIC联合程序性细胞死亡受体-1（PD-1）抗体治疗为免疫组，28例患者采取HAIC联合PD-1抗体免疫治疗与甲磺酸仑伐替尼胶囊靶向治疗为联合组。对比三组临床疗效、治疗前后胚抗原（CEA）、糖类抗原125（CA125）、甲胎蛋白（AFP）表达水平，不良反应发生率，并采用Piper疲乏修正量表（PFS-R）、世界卫生组织生存质量量表简表（WHOQOL-BREF）对两组癌因性疲乏程度及生存质量进行评价。结果   单纯化疗组、免疫组、联合组客观缓解率分别为15.00%、40.00%、64.29%，疾病控制率为30.00%、66.67%、82.14%，联合组高于单纯化疗组与免疫组（χ ² =11.720，P=0.003；χ ² =13.890，P＜0.001）；治疗后三组患者CEA、CA125、AFP水平均降低，且联合组［CEA：（13.62±4.24）ng/mL、CA125：（31.62±13.66）U/mL、AFP：（35.21±5.93）ng/mL］低于免疫组［（17.85±3.32）ng/mL、（59.26±9.35）U/mL、（42.12±4.12）ng/mL］及单纯化疗组［（23.73±4.79）ng/mL、（64.57±5.23）U/mL、（47.46±5.32）ng/mL］，对比差异有统计学意义（F=7.698，P＜0.001；F=11.480，P＜0.001；F=14.952，P＜0.001；P＜0.05）；所有患者均无5级不良反应及严重肝功能损害出现，且三组血小板减少、白细胞减少、腹痛、呕吐、消化道出血、厌食等不良反应发生率对比差异无统计学意义（P＞0.05）；治疗后三组患者PFS-R评分均降低，联合组（3.85±1.13）分低于免疫组（5.39±1.25）分及单纯化疗组（6.33±1.26）分，WHOQOL-BREF评分均升高，联合组（348.58±66.12）分高于免疫组（297.24±72.21）分及单纯化疗组（256.35±41.67）分，对比差异有统计学意义（F=2.526，P=0.014；F=2.167，P=0.033）。结论   免疫及靶向药物联合肝动脉灌注化疗治疗晚期肝癌疗效显著，可有效控制疾病进展的同时，降低机体肿瘤标志物水平，安全性可控，同时可改善患者生存质量，减轻癌因性疲乏程度。

       Objective  To explore the clinical efficacy of immune and targeted drugs combined with hepatic artery infusion chemotherapy（HAIC）in the treatment of advanced liver cancer．Methods  A retrospective analysis was conducted on 78 patients with advanced liver cancer admitted to our hospital from January 2021 to January 2024．Among them，20 patients were treated with simple HAIC and divided into a single chemotherapy group．Thirty patients were treated with HAIC combined with PD-1 antibody，and divided into an immune group．Twenty-eight patients were treated with HAIC combined with PD-1 antibody immunotherapy and lenvatinib mesylate capsule targeted therapy，and divided into a combination group．The clinical efficacy of three groups，the expressionlevels of CEA，CA125，AFP，and incidence of adverse reactions before and after treatment were compared．Piper Fatigue Correction Scale（PFS-R）and the WHO QOL-BREF were used to assess cancer-related fatigue in both groups．The degree of fatigue and quality of life were assessed．Results  The objective response rates of the simple chemotherapy group，the immune group，and the combination group were 15.00%，40.00% and 64.29%，respectively．The disease control  rates were 30.00%，66.67% and 82.14%，respectively．The indicators above of the combination group was significantly higher than those in the simple chemotherapy group and the immune group（χ ² =11.720，P=0.003；χ ² =13.890，P＜0.001；P＜0.05）．After treatment，the levels of CEA，CA125 and AFP were all decreased in the three groups，and those in the combined group （CEA［13.62±4.24］ng/mL，CA125［31.62±13.66］U/mL，AFP：Ng/mL［35.21±5.93］）were lower than those in the immune group（17.85±3.32 ng/mL，59.26±9.35 U/mL，/ 42.12±4.12 ng/mL）and single chemotherapy group（23.73±4.79 ng/mL，64.57±5.23 U/mL47.46±5.32］ng/mL），the differences were statistically significant（F=7.698，P＜0.001；F=11.480，P＜0.001；F=14.952，P＜0.001；P＜0.05）．All patients had no grade 5 adverse reactions or severe liver function damage，and there was no statistically significant difference in the incidence adverse reactions such as thrombocytopenia，leukopenia，abdominal pain，vomiting，gastrointestinal bleeding，and anorexia among the three groups（P＞0.05）．After treatment，the PFS-R score of the three groups was decreased，and the combined group（3.85±1.13）score was lower than that of the immune group（5.39±1.25）and the chemotherapy group（6.33±1.26）．While the WHOQOL-BREF score was increased，the score of combination group（348.58±66.12）was higher than that of immune group（297.24±72.21）and chemotherapy group（256.35±41.67），and the difference was statistically significant（F=2.526，P=0.014；F=2.167，P=0.033；P＜0.05）．Conclusions  The combination of immune and targeted drugs with hepatic artery infusion chemotherapy has a significant therapeutic effect on advanced liver cancer．It can effectively control disease progression，reduce tumor marker levels in the body，improve patient quality of life，and alleviate cancer-related fatigue，with controllable safety